Blue Ox Healthcare Partners has announced it led a $52 million series E investment in Epic Sciences.

Epic Sciences, based in San Diego, is a developer of diagnostics designed to advance the treatment and management of cancer, including a predictive test the company says determines how cancer cells will respond to a therapy.

Blue Ox, based in New York, is private equity investment firm focused on providing capital to growth stage healthcare companies. Founded in 2009, the firm focuses on businesses in the middle market, specifically targeting those companies with commercial products and solutions in healthcare services, healthcare IT, and medical and life sciences technologies.

Participants in the financing round also included new investors Deerfield Management and Varian and existing investors Altos Capital Partners, Genomic Health, Domain Associates, VI Ventures, Alexandria Venture Investments and Sabby Management, according to a news release.

Proceeds are expected to be used to accelerate Epic’s clinical studies and execution of its growth plan.